S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving gemcitabine directly into the bladder after surgery may kill more tumor cells. It is
not yet known whether giving gemcitabine directly into the bladder is more effective than a
placebo in treating bladder cancer.
PURPOSE: This randomized phase III trial is studying gemcitabine to see how well it works
when given directly into the bladder compared with a placebo after surgery in treating
patients with newly diagnosed or recurrent bladder cancer.